SGX Pharmaceuticals, Inc. (SGXP)

[surf1944]

SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Tuesday May 13, 6:00 am ET
Conference call scheduled today at 8:00 a.m. Pacific Time

SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP - News) today announced its financial results for the first quarter of 2008. For the three months ending March 31, 2008, the Company posted total revenues of $17.0 million and net income of $3.7 million. The revenue includes $10.8 million of revenue earned in the quarter that was attributable to the one-time recognition of the remaining portion of an upfront payment, which had not yet been recognized, related to the Company's collaboration with Novartis. Cash, cash equivalents and short-term investments totaled $30.9 million at March 31, 2008 compared to $39.0 million at December 31, 2007.

"Our team has had a busy and productive quarter," said Mike Grey, President and Chief Executive Officer of SGX. "IND enabling studies are continuing on our MET inhibitor, SGX126, and we now have a better understanding of the nature of the toxicity observed with SGX523. In addition, the progress we are making in our preclinical and late stage discovery programs is encouraging, as we work to build a robust pipeline of targeted oncology therapies. We are also pursuing a number of potential partnering opportunities for our programs, with the objective of expanding our revenue base."

Pipeline Update
http://biz.yahoo.com/prnews/080513/latu067.html?.v=101